For the quarter ending 2025-09-30, INMB had -$5,640K decrease in cash & cash equivalents over the period. -$5,632K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,472 | -34,197 |
| Stock-based compensation | 2,984 | 3,610 |
| Gain on settlement of accounts payable | 626 | - |
| Depreciation expense | 28 | - |
| Impairment of acquired in-process research and development intangible assets | 0 | 16,514 |
| Research and development tax credit receivable | 99 | 424 |
| Other tax receivable | 210 | 322 |
| Prepaid expenses | -33 | 174 |
| Accounts payable and accrued liabilities related parties | - | 159 |
| Other assets | 176 | 491 |
| Accounts payable and accrued liabilities | -170 | 1,132 |
| Accretion of debt discount | - | 0 |
| Deferred liabilities | -511 | -6 |
| Prepaid expenses related party | - | 0 |
| Operating lease liabilities | -61 | - |
| Net cash used in operating activities | -5,439 | -14,199 |
| Purchase of equipment | 193 | 706 |
| Net cash used in investing activities | -193 | -706 |
| Repayments of debt | - | 0 |
| Net proceeds from sale of common stock and warrants | 0 | 27,544 |
| Exercise of warrants for cash | 0 | 1 |
| Net cash provided by financing activities | 0 | 27,545 |
| Impact on cash from foreign currency translation | -8 | -188 |
| Net increase (decrease) in cash and cash equivalents | -5,640 | 12,452 |
| Cash and cash equivalents at beginning of period | 20,922 | - |
| Cash and cash equivalents at end of period | 27,734 | - |
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)